Orudis Hart forðahylki 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

orudis hart forðahylki 100 mg

sanofi-aventis norge as - ketoprofenum inn - hart forðahylki - 100 mg

Pentavac Stungulyfsstofn og dreifa, dreifa Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pentavac stungulyfsstofn og dreifa, dreifa

sanofi pasteur* - filamentous haemagglutinin; poliovirus inactivated type 2; poliovirus inactivated type 3; diphtheria toxoid; tetanus toxoid; poliovirus inactivated type 1; pertussis toxoid; haemophilus influenzae type b - stungulyfsstofn og dreifa, dreifa

Solian Tafla 200 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

solian tafla 200 mg

sanofi-aventis norge as - amisulpridum inn - tafla - 200 mg

Solian Tafla 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

solian tafla 50 mg

sanofi-aventis norge as - amisulpridum inn - tafla - 50 mg

Repevax Stungulyf, dreifa áfyllt sprauta Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

repevax stungulyf, dreifa áfyllt sprauta

sanofi pasteur* - tetanus toxoid; diphtheria toxoid; pertussis toxoid; filamentous haemagglutinin; pertussis fimbrial agglutinogens (fim) 2 and 3; pertactin; poliovirus (inactivated) type 1 (mahoney strain); poliovirus (inactivated) type 2 (mef-1 strain); poliovirus (inactivated) type 3 (saukett strain) - stungulyf, dreifa - áfyllt sprauta

Libtayo Evrópusambandið - íslenska - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - krabbamein, squamous cell - Æxlishemjandi lyf - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Stamaril Stungulyfsstofn og leysir, dreifa Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stamaril stungulyfsstofn og leysir, dreifa

sanofi pasteur* - gulusóttarveira 17d-204 stofn (lifandi, veikluð) - stungulyfsstofn og leysir, dreifa

Cordarone Tafla 200 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cordarone tafla 200 mg

sanofi-aventis norge as - amiodaronum hýdróklóríð - tafla - 200 mg

Cordarone Tafla 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cordarone tafla 100 mg

sanofi-aventis norge as - amiodaronum hýdróklóríð - tafla - 100 mg

Klexane Stungulyf, lausn áfyllt sprauta 100 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

klexane stungulyf, lausn áfyllt sprauta 100 mg/ml

sanofi-aventis norge as - enoxaparinum natricum inn - stungulyf, lausn - áfyllt sprauta 100 mg/ml